Nurse Practitioner, Family · Ocean View, DE
NPI
1629625603
Since 2019
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
96 Atlantic Ave Ste 101
Ocean View, DE, 19970
Phone (302) 541-4460
Groups this clinician bills Medicare through
Medicare paid, 2024
$174K
10,062 services
Medicare patients, 2024
1,285
Average age 76
Drug cost, 2024
$6.0M
27,550 prescriptions
Company payments, 2025
$403
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael P Boyle was code J1306 (injection, inclisiran, 1 mg), 6,532 times for 22 patients. In total Michael P Boyle billed 10,062 services in 12 codes, and Medicare paid $174K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 6,532 | 22 | $9.53 | $62K |
| 93000 Electrocardiogram | Office | 983 | 862 | $8.77 | $8,620 |
| 99214 Office E&M - Established | Office | 784 | 667 | $78.98 | $62K |
| 93793 Care Management/Coordination | Office | 587 | 198 | $7.11 | $4,171 |
| 99213 Office E&M - Established | Office | 565 | 520 | $55.45 | $31K |
| 85610 Clinical Chemistry | Office | 529 | 187 | $4.20 | $2,222 |
| 99211 Office E&M - Established | Office | 25 | 24 | $15.71 | $393 |
| 96372 Injection Administration | Office | 25 | 24 | $9.65 | $241 |
| 99204 Office E&M - New | Office | 24 | 24 | $103.21 | $2,477 |
By year: 2022 $1,634 for 30 services; 2023 $113K for 4,110 services; 2024 $174K for 10,062 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85610 Clinical Chemistry | 529 | 187 | $4.20 | $2,222 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael P Boyle prescribed most often to Medicare patients was Atorvastatin Calcium, with 2,324 prescriptions and refills. In total Michael P Boyle wrote 27,550 Medicare prescriptions that cost $6.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 2,324 | 6,530 | 871 | $34K |
| Eliquis Apixaban | 2,054 | 4,737 | 754 | $2.7M |
| Metoprolol Succinate Generic | 1,924 | 5,484 | 754 | $37K |
| Rosuvastatin Calcium Generic | 1,726 | 4,900 | 638 | $51K |
| Amlodipine Besylate Generic | 1,451 | 4,145 | 576 | $13K |
| Carvedilol Generic | 1,333 | 3,596 | 488 | $15K |
| Metoprolol Tartrate Generic | 1,237 | 3,358 | 459 | $9,738 |
| Furosemide Generic | 1,187 | 3,020 | 469 | $7,056 |
| Lisinopril Generic | 981 | 2,762 | 345 | $8,906 |
| Losartan Potassium Generic | 887 | 2,490 | 357 | $11K |
| Xarelto Rivaroxaban | 848 | 1,979 | 319 | $1.1M |
| Ezetimibe Generic | 688 | 1,944 | 245 | $39K |
| Potassium Chloride Generic | 680 | 1,655 | 237 | $16K |
| Valsartan Generic | 594 | 1,606 | 226 | $27K |
| Clopidogrel Clopidogrel Bisulfate | 567 | 1,561 | 227 | $7,798 |
Brand drugs: 4,796 claims; generic drugs: 22,754 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael P Boyle $403 ($403 in general payments such as food, travel and fees) from 10 companies. The largest payer was Medtronic, Inc. with $110.
| Company | Payments | Amount |
|---|---|---|
| Medtronic, Inc. MDT | 1 | $110 |
| Merck Sharp & Dohme LLC MRK | 4 | $67.23 |
| Pfizer Inc. PFE | 3 | $59.14 |
| Novo Nordisk Inc NVO | 2 | $39.61 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $31.85 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $21.33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $20.94 |
| E.R. Squibb & Sons, L.L.C. BMY | 1 | $19.58 |
| Amgen Inc. AMGN | 1 | $18.36 |
| Scpharmaceuticals Inc. SCPH | 1 | $15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.